

# A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency

Ferdows Atiq<sup>1</sup> · Patricia M.L.A. van den Bemt<sup>1</sup> · Frank W.G. Leebeek<sup>2</sup> · Teun van Gelder<sup>1,3</sup> · Jorie Versmissen<sup>3</sup>

Received: 9 March 2015 / Accepted: 28 May 2015 / Published online: 14 June 2015  
© The Author(s) 2015. This article is published with open access at Springerlink.com

## Abstract

**Purpose** Although therapeutic dosages of most low-molecular-weight heparins (LMWHs) are known to accumulate in patients with renal insufficiency, for the lower prophylactic dosages this has not been clearly proven. Nevertheless, dose reduction is often recommended. We conducted a systematic review to investigate whether prophylactic dosages of LMWH accumulate in renal insufficient patients.

**Methods** A comprehensive search was conducted on 17 February 2015 using Embase, Medline, Web of Science, Scopus, Cochrane, PubMed publisher, and Google scholar. The syntax emphasized for LMWHs, impaired renal function, and pharmacokinetics. The search yielded 674 publications. After exclusion by reading the titles, abstracts, and if necessary the full paper, 11 publications remained.

**Results** For dalteparin and tinzaparin, no accumulation was observed. Enoxaparin, on the other hand, did lead to accumulation in patients with renal insufficiency, although not in patients undergoing renal replacement therapy. Bemiparin and certoparin also did show accumulation. No data were available for nadroparin.

**Conclusions** In this systematic review, we show that prophylactic dosages of tinzaparin and dalteparin are likely to be safe in patients with renal insufficiency and do not need dose reduction based on the absence of accumulation. However, prophylactic dosages of enoxaparin, bemiparin, and certoparin did show accumulation in patients with a creatinine clearance (CrCl) below 30 ml/min, and therefore, dose reduction is required. The differences in occurrence of accumulation seem to depend on the mean molecular weight of LMWHs.

**Keywords** Clinical trials · Heparins · Pharmacodynamics · Heparins · Venous thrombosis

## Introduction

Low-molecular-weight heparins (LMWHs) are anticoagulants made by depolymerization of unfractionated heparin (UFH) [1, 2]. In the last decades, LMWHs have largely replaced UFH as anticoagulants, because they are at least equally effective in prevention and treatment of venous thromboembolisms (VTEs) and have many practical advantages, most importantly the possibility of subcutaneous administration without the need of routine laboratory monitoring of the anticoagulant response [3–8]. Moreover, LMWHs have a more predictable anticoagulant response, longer half-life (allowing once or twice daily administration), and a dose-independent elimination and they cause less heparin-induced thrombocytopenia [1, 2, 9, 10]. There is conflicting evidence whether bleeding complications differ between LMWHs and UFH, although a Cochrane analysis showed that LMWHs reduce the occurrence of major bleedings [8, 11–14].

The molecular weights of the various LMWHs differ. Tinzaparin has the highest average molecular weight (6500 Da), while certoparin has the lowest average molecular

**Electronic supplementary material** The online version of this article (doi:10.1007/s00228-015-1880-5) contains supplementary material, which is available to authorized users.

✉ Jorie Versmissen  
j.versmissen@erasmusmc.nl

<sup>1</sup> Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands

<sup>2</sup> Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands

<sup>3</sup> Department of Internal Medicine, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands

weight (3800 Da) [13]. Pharmacokinetics of different LMWHs vary: they differ in elimination half-life, clearance, and bioavailability [15, 16]. This might be a consequence of the differences in molecular weight. Also with regard to pharmacodynamics, LMWHs vary: anti-Xa/anti-IIa activity ratios range between 1.5 and 2.5 (tinzaparin and certoparin) to 3.6–6.5 (reviparin) [13].

Since LMWHs are mainly excreted by the kidney, they may accumulate in patients with renal insufficiency increasing the risk of bleeding [17–19]. Due to above-described differences in pharmacokinetics, data on accumulation in renal insufficiency cannot be easily converted from one LMWH to another [2]. For instance, therapeutic dosages of different LMWHs do not all accumulate in patients with renal insufficiency: nadroparin and enoxaparin were found to accumulate, while tinzaparin did not [20–26]. For LMWHs that accumulate in a therapeutic dosage, dose reduction is often recommended. Also for the lower prophylactic dosages, such dose reductions have been suggested, especially for high prophylactic dosages such as those used in cancer patients or in high-risk surgery [24, 27–29].

Even in this era of novel oral anticoagulants, LMWHs will stay important for the initial treatment of VTE during the first 5–7 days in patients treated with dabigatran and edoxaban, as well as for prophylaxis of VTE. Especially for patients with severe renal insufficiency in which case the novel oral anticoagulants are contraindicated, it remains important to know whether LMWHs can be prescribed safely.

Therefore, we conducted a systematic review to investigate whether prophylactic dosages of various LMWHs lead to accumulation defined as an increase in anti-Xa activity and whether accumulation depends on molecular weight of the LMWH.

## Materials and methods

The meta-analysis was prepared in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [30]. No prespecified formal protocol was registered.

### Article search

A comprehensive, systematic literature search has been conducted on 17 February 2015 using Embase, Medline, Web of Science, Scopus, Cochrane, PubMed publisher, and Google scholar. The syntax emphasized for LMWHs, impaired renal function, and pharmacokinetics using synonyms and relevant terms. The search terms as used in Embase, as an example, are shown in a [supplemental file](#). In addition to the search results, we manually searched reference lists of all relevant articles for additional studies.

### Inclusion criteria and exclusion criteria (eligibility criteria)

We only included articles in English on prophylactic LMWH treatment, studying at least ten patients (non-pregnant and with no children) with renal impairment. We defined accumulation as an increase in anti-Xa activity after consecutive administration for several days. Therefore, we excluded studies which did not administer LMWH on consecutive days (except for studies in patients receiving renal replacement therapy) and did not measure anti-Xa activity on multiple days while giving LMWH. We excluded case reports, overviews, expert opinions, recommendations, reviews, and replies on articles. Abstracts of unpublished data were not excluded; authors were approached for additional information.

### Study selection and data collection

A single reviewer excluded articles that did not meet the eligibility criteria by using the title and abstract. If necessary, the full text was read. If the reviewer could not decide whether to exclude the article, a second reviewer was asked for advice and both met to reach a consensus. Furthermore, a single reviewer collected relevant data from the included articles for the review.

### Risk of bias

Risk of bias was evaluated at study level using the Cochrane Risk of Bias assessment tool. The criteria on random sequence generation, allocation, and blinding were disregarded.

## Results


### Study selection

The search yielded 1387 articles from which 713 were duplicates. Figure 1 shows a flow diagram illustrating literature evaluation.

### Characteristics

Table 1 shows the study and patient characteristics. We included 11 articles of which one was on LMWH in continuous venovenous hemofiltration (CVVH) and one on hemodialysis patients. Five studies examined dalteparin accumulation, and five articles examined enoxaparin [31–37, 40, 41]. For tinzaparin, bemiparin, and certoparin, there was one study for each LMWH [35, 38, 39].

All studies were conducted prospectively. Two were randomized trials, and eight were cohort studies. Only one study did report clear prespecified primary outcomes. The number of



**Fig. 1** Flow diagram illustrating literature evaluation

patients ranged between 12 and 138. Three studies only included patients on an intensive care unit (ICU), and three studies only included elderly patients (Table 1). The follow-up length per patient was 4 days to 3 weeks. Accumulation was mainly assessed by measuring peak anti-Xa activity or trough anti-Xa activity (Table 2). Six studies reported clinical outcomes like hemorrhagic events, thrombosis, and mortality rates.

### Dalteparin

Dalteparin accumulation was studied in five articles. In patients on a general medical or surgical ward, no accumulation was found in a total of 157 patients by measuring peak anti-Xa activity on day 6 or day 10 [32, 34].

At the ICU, trough and peak anti-Xa activity did not show accumulation on day 9 or day 12 in a total of 157 patients not undergoing CVVH [31, 33].

Also in hemodialysis patients ( $n=7$ ) prescribed 2500 IU dalteparin during hemodialysis sessions for 4 weeks, anti-Xa activity at different time points (1, 2, 3, 4, 24, and 28 h postinjection) were not significantly different between week 1 and week 4 [40]. The patients underwent hemodialysis sessions three times a week for 4 h.

### Enoxaparin

Three studies of which two in patients older than 75 years examined enoxaparin accumulation in, respectively, 125, 28, and 48 non-dialysis patients [35–37]. The studies in the elderly with CrCl 20–50 ml/min found a significantly higher maximum concentration ( $C_{max}$ ), area under the curve (AUC), and trough anti-Xa activity (24 h postinjection) after 8 days

administration and a higher peak anti-Xa activity after 10 days, compared to patients with better renal function [35, 36]. The other study in patients with different severity of renal insufficiency found accumulation (a significantly higher  $C_{max}$ , longer half-life, higher AUC) already on day 4 in patients with CrCl  $\leq 30$  ml/min [37].

Hemodialysis patients ( $n=7$ ) prescribed 40 mg enoxaparin at hemodialysis sessions for 4 weeks, anti-Xa activity at different time points postinjection were not significantly different between week 1 and week 4 [40]. Also in ICU patients ( $n=12$ ) undergoing CVVH with a flow rate of 30 ml/kg/h, no accumulation of enoxaparin (30 mg daily) was found [41].

### Tinzaparin, bemiparin, and certoparin

Administration of 4500 IU tinzaparin for 8 days in 27 patients older than 75 years with CrCl 20–50 ml/min and body weight below 65 kg did not lead to significant changes in  $C_{max}$ , AUC, and trough anti-Xa activity (24 h postinjection) [35].

For 3500 IU bemiparin,  $C_{max}$  was higher and mean half-life was 2–4 h prolonged in patients with severe renal insufficiency after 4 days administration in 48 patients [38]. AUC significantly increased with the degree of renal insufficiency.

For 3000 IU certoparin,  $C_{max}$  and AUC were significantly higher in patients with renal insufficiency compared to healthy controls after 5 days administration in 24 patients [39].

### Adverse events

Six studies reported VTEs and bleeding events, although all were underpowered to find significant correlations [31–36]. In three of these studies, anti-Xa activity was

**Table 1** Study characteristics of included studies including patient characteristics and outcome measurements

Study	Study design	LMWH	Patients (n)	Groups	Patient characteristics	Follow-up	Outcomes
Rabbat 2005 <sup>a</sup> [31]	Cohort	Dalteparin 5000 IU	19	NA	IC patients with CrCl $\geq$ 30	12 days <sup>f</sup> (IQR 8–24)	Trough (22–23 h postinjection) and peak anti-Xa
Schmid 2009 <sup>b</sup> [32]	Cohort	Dalteparin <50 kg 2500 IU 50–100 kg 5000 IU >100 kg 7500 IU	42	n=18 CrCl $\geq$ 60 n=15 CrCl 30–59 n=9 CrCl<30	General medical and surgical ward	3 weeks	Peak anti-Xa
Douketis 2008 <sup>a</sup> [33]	Cohort	Dalteparin 5000 IU	138	NA	ICU patients with CrCl<30 ml/min	9 days <sup>f</sup> (IQR 5–15)	Trough (20 h postinjection) and peak anti-Xa
Tincaei 2006 <sup>b</sup> [34]	Cohort	Dalteparin High risk 5000 IU Low risk 2500 IU	115	n=9 CrCl 60–89 n=73 CrCl 30–59 n=24 CrCl<30	Elderly patients (>65 years) with acute illness	6 days	Peak anti-Xa
Mahe 2007 <sup>a</sup> [35]	Randomized	Tinzaparin 4500 IU Enoxaparin 4000 IU	50	n=27 tinzaparin; n=28 enoxaparin	CrCl 20–50 ml/min, >75 years and weight<65 kg	8 days	C <sub>max</sub> , AUC, and trough anti-Xa (24 h postinjection)
Mahe 2007 <sup>a</sup> [36]	Cohort	Enoxaparin 4000 IU	125	CrCl 51–80 CrCl 41–50 CrCl 31–40 CrCl 20–30	Elderly patients (>75 years) with acute medical illness	10 days	Peak anti-Xa. Maximum value per patient was used in the analysis
Sanderink 2002 <sup>c</sup> [37]	Cohort	Enoxaparin 4000 IU	48 (12/group)	CrCl>80 50<CrCl $\leq$ 80 30<CrCl $\leq$ 50 CrCl $\leq$ 30	18–75 years old. BMI 18–30	4 days	C <sub>max</sub> , AUC, half-life, and CL/F
Rico 2014 <sup>d</sup> [38]	2-period cohort	Bemiparin 3500 IU	48	n=25 CrCl>80 n=8 50 $\leq$ CrCl $\leq$ 80 n=7 30 $\leq$ CrCl<50 n=8 CrCl<30 n=12 normal renal function	Persons with normal renal function had no medical history	4 days	C <sub>max</sub> , AUC, half-life, and CL/F
Alban 2013 <sup>e</sup> [39]	Cohort	Certoparin 3000 IU	24	n=8 CrCl<30 n=12 normal renal function		5 days	C <sub>max</sub> , AUC, half-life
Polkinhorne 2002 <sup>e</sup> [40]	Randomized	Enoxaparin 4000 IU Dalteparin 2500 IU	21 HD	n=12 CrCl<30 Each drug n=7	Thrice-weekly hemodialysis patients	4 weeks	Anti-Xa activity 1, 2, 3, 4, 24, and 28 h postinjection
Brown 2010 <sup>e</sup> [41]	Cohort	Enoxaparin 3000 IU	12 CVVH	NA	ICU patients receiving CVVH 30 ml/kg/h	9 days <sup>g</sup>	Trough anti-Xa levels

All studies administered a once daily dosage. Peak anti-Xa: activity 4 h postinjection in all studies

CrCl was estimated using the <sup>a</sup> Cockcroft Gault formula; <sup>b</sup> MDRD formula; <sup>c</sup> formula: (urine creatinine (mg/dl) $\times$ 24 h urine volume (ml)/1440 min)/( [serum creatinine from days 1, 4, and 5 (mg/dl)]/3); <sup>d</sup> formula: urine creatinine concentration  $\times$  24 h collected urine volume/plasma creatinine concentration  $\times$  24  $\times$  60. <sup>e</sup> CrCl formula is not mentioned. <sup>f</sup> Median length of stay. <sup>g</sup> Time between first and last anti-Xa in whole population

ICU intensive care unit, CrCl creatinine clearance in ml/min, IQR interquartile range, n number of patients, C<sub>max</sub> maximum concentration, AUC area under the curve, BMI body mass index, CL/F apparent total body clearance, HD hemodialysis, CVVH continuous venovenous hemofiltration

**Table 2** Outcomes of included studies

LMWH	Parameter	Results					
Dalteparin 5000 IU [31]	Trough anti-Xa	Three patients value(s)>detection threshold; none above accumulation threshold					
	Peak anti-Xa	Mean 0.30 U/ml (95 % CI 0.27–0.33)					
		Day 1			Day 10		
Dalteparin 2500, 5000, and 7500 IU [32]	Peak anti-Xa (range)	CrCl>60 0.28 <sup>b</sup> (0.20–0.32)	CrCl 30–59 0.31 <sup>b</sup> (0.23–0.46)	CrCl<30 0.28 <sup>b</sup> (0.23–0.33)	CrCl>60 0.27 <sup>a,b</sup> (0.16–0.35)	CrCl 30–59 0.48 <sup>a,b</sup> (0.31–0.51)	CrCl<30 0.39 <sup>a,b</sup> (0.31–0.50)
Dalteparin 5000 IU [33]	Trough anti-Xa	Seven patients value(s)>detection threshold; none above accumulation threshold					
		Day 3		Day 10		Day 17	
	Peak anti-Xa (range)	0.29 (0.20–0.42) <sup>a</sup>		0.35 (0.24–0.43) <sup>a</sup>		0.34 (0.27–0.45) <sup>a</sup>	
Dalteparin 2500 and 5000 IU [34]		Day 6			<i>p</i> value		
	Peak anti-Xa (range)	CrCl>60 0.030 (0.086) <sup>b</sup>	CrCl 30–59 0.033 (0.075) <sup>b</sup>	CrCl<30 0.048 (0.084) <sup>b</sup>			
Enoxaparin 4000 IU Tinzaparin 4500 IU [35]	<i>C</i> <sub>max</sub>	Enoxaparin 0.55 (0.14)	Tinzaparin 0.44 (0.16)	Enoxaparin 0.67 (0.23)	Tinzaparin 0.46 (0.19)	Enoxaparin <0.001	Tinzaparin 0.296
	AUC	354 (119)	252 (103)	447 (218)	273 (111)	<0.001	0.11
	Trough	0.06 (0.06)	0.05 (0.04)	0.11 (0.10)	0.06 (0.06)	0.013	0.17
Enoxaparin 4000 IU [36]	Anti-Xa <sub>max 1–10</sub>	CrCl 51–80 0.60 (0.16)	CrCl 41–50 0.61 (0.17)	CrCl 31–40 0.61 (0.24)	CrCl 20–30 0.72 (0.27)		
	<i>p</i> value	0.030 <sup>c</sup>	0.039 <sup>c</sup>	0.039 <sup>c</sup>	Ref		
Enoxaparin 4000 IU [37]		Severe RI					
	<i>C</i> <sub>max</sub>	10–35 % higher					
	AUC <sub>(0–24)</sub>	65 % higher (day 4)					
	CL/F	27 % (day 1), 39 % (day 4)					
	<i>t</i> <sub>1/2λz</sub>	Increased with the degree of RI ( <i>p</i> <0.012)					
Bemiparin 3500 IU [38]		Severe RI					
	<i>C</i> <sub>max</sub>	Higher					
	<i>t</i> <sub>1/2</sub>	2–4 h prolonged					
	CL/F	Lower					
	AUC	Increased with the degree of RI					
Certoparin 3000 IU [39]		Severe RI			Ratio severe RI/normal renal function		
	<i>C</i> <sub>max</sub> day 5	0.27 (range 0.16–0.70)			1.39 (95 % CI 1.04–1.85)		
	AUC <sub>(0–24)</sub>	2.28 (range 1.35–5.11)			1.52 (95 % CI 1.07–2.17)		
Enoxaparin 4000 IU, Dalteparin 2500 IU [40]		Week 1 <sup>a</sup>			Week 4 <sup>a</sup>		
	Anti-Xa (SEM)	Dalteparin 0.2 (0.035)	Enoxaparin 0.38 (0.028)	Dalteparin 0.26 (0.038)	Enoxaparin 0.40 (0.055)		
Enoxaparin 3000 IU [41]	Trough anti-Xa	Mean 0.11 (range 0.01–0.27, SD 0.07). None above accumulation threshold.					

All studies administered a once daily dosage. Peak anti-Xa: activity 4 h postinjection in all studies (all anti-Xa activity in IU/ml  
*IQR* interquartile range, *CrCl* creatinine clearance in ml/min, *C*<sub>max</sub> maximum concentration, *AUC* area under the curve, *Anti-Xa*<sub>max 1–10</sub> maximum anti-Xa activity in 10 days, *AUC*<sub>(0–24)</sub> area under the 24 h plasma activity time curve, *CL/F* apparent total body clearance, *RI* renal insufficiency, *t*<sub>1/2</sub> elimination half-life, *t*<sub>1/2λz</sub> apparent terminal elimination half-life, *SEM* standard error of the mean

<sup>a</sup> No significant changes between day 1 and day *x*

<sup>b</sup> No significant changes between groups on day *x*

<sup>c</sup> Compared to CrCl 20–30 ml/min

undetectable during bleeding [31, 33, 34]. Five serious bleeding complications were reported when using

enoxaparin, but anti-Xa activity in these patients was the same as in those without bleeding (*p*=0.77) [36].

**Table 3** Accumulation dependency on molecular weight

LMWH	Mean molecular weight (Da) [13, 47]	Accumulation therapeutic	Accumulation prophylactic
Bemiparin	3600	CrCl<30 ml/min [38]	CrCl<30 ml/min [38]
Certoparin	3800	CrCl<30 ml/min [48]	CrCl<30 ml/min [39]
Nadroparin	4300	Yes <sup>a</sup> [20]	No conclusion <sup>b</sup>
Enoxaparin	4500	CrCl<30 ml/min [21–24]	CrCl<30 ml/min 4 days [37] and 20–50 ml/min 8 days [35]
Dalteparin	6000	CrCl<30 ml/min after 6 days [32], but not after 3 [43]	No <sup>c</sup> [31–34]
Tinzaparin	6500	No <sup>d</sup> [25, 26]	No <sup>d</sup> [35]

CrCl creatinine clearance

<sup>a</sup> Only correlation GFR/anti-Xa activity reported, no specific accumulation limit

<sup>b</sup> Only one multiple dose study in six patients with CrCl above 30 ml/min and one single intravenous dose study [45, 46]

<sup>c</sup> Largest study no lower limit for CrCl<sup>33</sup>

<sup>d</sup> CrCl>20 ml/min

## Discussion

In this systematic review, we show that prophylactic dosages of dalteparin and tinzaparin did not accumulate in patients with renal insufficiency, while prophylactic dosages of enoxaparin, bemiparin, and certoparin did accumulate. Dalteparin also showed no accumulation in hemodialysis patients. Surprisingly, enoxaparin did not show accumulation in hemodialysis and CVVH patients, which might be due to removal by renal replacement therapy [42]. No data are available for nadroparin in patients with renal insufficiency.

These results are in accordance with studies on therapeutic dosages, except for dalteparin. Dalteparin is the only LMWH that appears to accumulate when used in a therapeutic dosage, while in studies using prophylactic dosages no accumulation was detected [31–34, 43]. A single-dose study showed reduced elimination of prophylactic dalteparin in patients with renal insufficiency, but apparently clearance is sufficient to prevent accumulation [31–34, 44].

Data on assessment of accumulation on prophylactic nadroparin in renal insufficiency are lacking. Only one multiple-dose study in six patients with CrCl above 30 ml/min and one single-dose study were conducted [45, 46].

Our findings confirm the theory that accumulation seems to depend on the mean molecular weight of LMWHs as shown in Table 3. LMWHs with the lowest molecular weight (enoxaparin, bemiparin, certoparin, and nadroparin) all showed accumulation in a therapeutic dosage and a prophylactic dosage. Tinzaparin (the LMWH with the highest mean molecular weight) has shown not to accumulate in neither therapeutic nor prophylactic dosage. The most likely explanation for this counterintuitive relationship between size and

accumulation is that the larger molecules are less dependent on renal clearance [4, 28, 49, 50].

In patients undergoing renal replacement therapy, it has been shown that many LMWHs are safe to use even in therapeutic dosages [28, 51]. For assessment of accumulation, only a few studies have been conducted. Most of these studies were excluded from this review as they included a single bolus administration, a therapeutic dosage, or no anti-Xa activity measuring at multiple days. Dalteparin showed accumulation in hemodialysis patients if prescribed in a therapeutic dosage, but not in a prophylactic dosage, whereas accumulation was found for prophylactic dosage in peritoneal dialysis patients [19, 40, 52]. Prophylactic dosages of enoxaparin and prophylactic and therapeutic dosages of nadroparin showed no accumulation in hemodialysis and CVVH patients [40, 41, 53, 54]. Tinzaparin accumulation has been found in a therapeutic dose in hemodialysis patients, but in a prophylactic dose, anti-Xa activity returned to baseline in 24 h [52, 55]. In conclusion, for dalteparin accumulation in renal replacement therapy is comparable to accumulation in patients without renal replacement therapy, but in other LMWHs accumulation in renal replacement therapy seems not to depend on mean molecular weight of LMWHs. The mechanism for accumulation in renal replacement therapy is unknown, but the highly negative charge of LMWHs might play a role [52]. More studies are needed to assess LMWH accumulation in patients on renal replacement therapy.

The strength of this review is first that we included only articles that objectively observed accumulation based on anti-Xa activity rather than an accumulation prediction based on the half-life or the time it takes for anti-Xa activity to return to baseline. Second, by including the recent studies on bemiparin and certoparin, this paper confirms the earlier stated theory

that accumulation depends on the mean molecular weight of LMWHs.

A limitation might be that we did not include single-dose studies. However, a single-dose study is not suitable for objectively detecting accumulation [28, 32]. A significantly lower clearance or prolonged half-life for a LMWH in a single-dose study does not necessarily indicate that the LMWH accumulates, as is clear from the findings on dalteparin. Furthermore, follow-up of patients in some studies was relatively short (in some studies less than 1 week); however, if LMWHs would accumulate, this would be noticeable already after three dosages. Given the fact that patients tend to be discharged from the hospital within a few days, it is hardly possible to perform clinical studies with longer follow-up.

Another limitation might be that the risk of bias could not be assessed accurately. Considering bias across studies, we feel that a publication bias seems unlikely since both negative and positive outcomes in studies on accumulation have news value, and we included two abstracts of unpublished data. Furthermore, a possible confounder could be the difference in renal insufficiency onset (acute vs chronic) in different studies; however, there is no evidence that this can cause variance in anti-Xa activity.

A major limitation of all studies is that anti-Xa activity rather than hard clinical endpoints were studied. Although a study on hard clinical endpoints in patients with renal insufficiency is probably not feasible due to large numbers needed, it should be taken into account that the correlation between anti-Xa activity and occurrence of bleeding or VTE is not unambiguous [56–60]. The therapeutic and prophylactic target levels of anti-Xa activity are not supported by evidence of trials, but they are rather based on expert opinions [61, 62]. We also found in our review that in six studies that reported clinical outcomes, none of the patients with bleeding had higher anti-Xa activity than patients without bleeding [31–36]. However, the anti-Xa activity is considered to be the best test available to measure LMWH activity and to detect accumulation of LMWHs [4, 63].

In conclusion, for several LMWHs the guidelines that recommend dose reduction for prophylactic use in patients with renal insufficiency are evidence based, except for dalteparin, tinzaparin, and nadroparin. We recommend a dose reduction for prophylactic use of enoxaparin, bemiparin, and certoparin in patients with CrCl below 30 ml/min [24, 28, 29, 38, 39]. Prophylactic dosages of tinzaparin and dalteparin are likely to be safe in patients with renal insufficiency and do not need dose reduction. Studies are needed to assess accumulation of prophylactic dosages of nadroparin and for all LMWHs in patients undergoing renal replacement therapy.

**Acknowledgments** This work was funded by the Dutch Kidney Foundation (Safety of medication in renal insufficiency, MV 13.36)

**Authors' Contributions** F. Atiq contributed to the conception and design of the work, data acquisition and analysis, and writing of the manuscript. P.M.L.A. van den Bemt and F.W.G. Leebeek contributed to the conception and design of the work and revised the manuscript critically. T. van Gelder contributed to the conception and design of the work and data analysis and revised the manuscript critically. J. Versmissen contributed to the conception and design of the work, data acquisition and analysis, and writing and revising of the manuscript. All authors approved the final version of the manuscript.

**Conflict of interest** The authors declare that they have no competing interests.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

- Hirsh J, Levine MN (1992) Low molecular weight heparin. *Blood* 79(1):1–17
- Hetzel GR, Sucker C (2005) The heparins: all a nephrologist should know. *Nephrol Dial Transplant* 20(10):2036–2042
- Weitz JI (1997) Low-molecular-weight heparins. *N Engl J Med* 337(10):688–698
- Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest* 119(1 SUPPL):64S–94S
- Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. *Arch Intern Med* 161(10):1268–1279
- Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E (1992) Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet* 340(8812):152–156
- Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. *Ann Intern Med* 130(10):800–809
- Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA (1996) A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med* 335(10):701–707
- Frydman A (1996) Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. *Haemostasis* 26(Suppl 2):24–38
- Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 332(20):1330–1335
- Thorevska N, Amoaeng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA (2004) Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. *Chest* 125(3):856–863

12. Davis R, Faulds D (1997) Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. *Drugs Aging* 10(4):299–322
13. Boneu B (2000) Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? *Thromb Res* 100(2):V113–V120
14. van Dongen CJ, van den Belt AG, Prins MH, Lensing AW (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. *Cochrane Database Syst Rev* 4, Cd001100. doi:10.1002/14651858.CD001100.pub2
15. Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. *Semin Thromb Hemost* 26(Suppl 1):31–38
16. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thebault JJ (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins—dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). *Thromb Haemost* 73(4):630–640
17. Boneu B, Caranobe C, Sie P (1990) Pharmacokinetics of heparin and low molecular weight heparin. *Baillieres Clin Haematol* 3(3):531–544
18. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest* 126(3 SUPPL):188S–203S
19. Schmid P, Brodmann D, Fischer AG, Wuillemin WA (2010) Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis. *J Thromb Haemost* 8(4):850–852
20. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, D’Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B (1998) Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). *Thromb Haemost* 79(6):1162–1165
21. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM, Investigators TA (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 143(5):753–759
22. Bazinet A, Almanic K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L (2005) Dosage of enoxaparin among obese and renal impairment patients. *Thromb Res* 116(1):41–50
23. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. *J Clin Pharmacol* 43(6):586–590
24. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. *Ann Intern Med* 144(9):673–684
25. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselien B, Laurent M, Andruex JP, D’Urso M, Gaussem P (2000) Elderly patients treated with tinzaparin (innohep(registered trademark)) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. *Thromb Haemost* 84(5):800–804
26. Pautas E, Gouin I, Bellot O, Andruex JP, Siguret V (2002) Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. *Drug Saf* 25(10):725–733
27. Horlocker TT, Heit JA (1997) Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. *Anesth Analg* 85(4):874–885
28. Schmid P, Fischer AG, Wuillemin WA (2009) Low-molecular-weight heparin in patients with renal insufficiency. *Swiss Med Wkly* 139(31–32):438–452
29. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. *Ann Pharmacother* 43(6):1064–1083
30. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 6(7), e1000097. doi:10.1371/journal.pmed.1000097
31. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO, Lee KA, Cook RJ (2005) Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. *J Crit Care* 20(4):357–363. doi:10.1016/j.jcrc.2005.09.009
32. Schmid P, Brodmann D, Fischer AG, Wuillemin WA (2009) Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. *J Thromb Haemost* 7(4):552–558
33. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M (2008) Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. *Arch Intern Med* 168(16):1805–1812
34. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M (2006) Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. *Haematologica* 91(7):976–979
35. Mahe I, Aghassarian M, Drouet L, Bal Dit-Sollier C, Lacut K, Heilmann JJ, Mottier D, Bergmann JF (2007) Tinzaparin and enoxaparin given at prophylactic dose for 8 days in medical elderly patients with impaired renal function. A comparative pharmacokinetic study. *Thromb Haemost* 97(4):581–586
36. Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di Castillo H, Siguret V, Bergmann JF, Pautas E (2007) Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. *Drugs Aging* 24(1):63–71
37. Sanderink GJCM, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. *Thromb Res* 105(3):225–231
38. Rico S, Antonijoan RM, Ballester MR, Gutierrez I, Ayani I, Martinez-Gonzalez J, Borrell M, Fontcuberta J, Gich I (2014) Pharmacodynamics assessment of bempiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. *Thromb Res* 133(6):1029–1038
39. Alban S, Peterfai E, Melzer N, Hagedorn I, De Mey C (2013) Conventional prophylactic doses of certoparin do not cause exaggerated aXa-exposure in patients with severe renal insufficiency. *Hamostaseologie* 33(1):A65
40. Polkinghorne KR, McMahon LP, Becker GJ (2002) Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. *Am J Kidney Dis* 40(5):990–995
41. Brown LS, Bourne RS, Kitchen S, VanVeen J, Byrne S (2010) A service evaluation of venous thromboembolism prophylaxis with low molecular weight heparin (LMWH) in intensive care patients receiving continuous renal replacement therapy. *Intensive Care Med* 36:S293
42. Isla A, Gascon AR, Maynar J, Arzuaga A, Corral E, Martin A, Solinis MA, Munoz JL (2005) In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with

- acrylonitrile and polysulfone membranes. *Clin Ther* 27(9):1444–1451. doi:10.1016/j.clinthera.2005.09.008
43. Shprecher AR, Cheng-Lai A, Madsen EM, Cohen HW, Sinnott MJ, Wong ST, Billett HH (2005) Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. *Pharmacotherapy* 25(6):817–822
  44. Stobe J, Siegemund A, Achenbach H, Preiss C, Preiss R (2006) Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. *Int J Clin Pharmacol Ther* 44(10):455–465
  45. Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM (1991) Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. *Nephron* 59(4):543–545
  46. Alhenc-Gelas M, Rossert J, Jacquot C, Aiach M (1995) Pharmacokinetic study of the low-molecular-weight heparin fraxiparin in patients with nephrotic syndrome. *Nephron* 71(2): 149–152
  47. Martinez-Gonzalez J, Vila L, Rodriguez C (2008) Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. *Expert Rev Cardiovasc Ther* 6(6):793–802
  48. Alban S, Peterfai E, Melzer N, Hagedorn I, De Mey C (2013) Conventional therapeutic doses of certoparin do not lead to exaggerated aXa-levels in all the patients with severe renal insufficiency. *Hamostaseologie* 33(1):A64
  49. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC (1998) College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. *Arch Pathol Lab Med* 122(9):799–807
  50. Davies RG, Rayment R (2010) Primum non nocere—NICE guidelines on venous thromboembolism. *Anaesthesia* 65(8):774–778
  51. Lim W, Cook DJ, Crowther MA (2004) Safety and efficacy of low molecular weight heparins for hem dialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. *J Am Soc Nephrol* 15(12):3192–3206
  52. Rodger MA, Ramsay T, MacKinnon M, Westphal M, Wells PS, McCormick B, Knoll G (2012) Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial. *Am J Kidney Dis* 60(3):427–434
  53. Hene IZ, Wiertz NR, Van Schilfgaarde M, Wester JPI, Leyte A, Oudemans-Van Straaten HM (2009) Nadroparin anticoagulation in continuous venovenous hemofiltration (CVVH): kinetics and extracorporeal removal. *Intensive Care Med* 35:S44
  54. Nurmohamed MT, ten Cate J, Stevens P, Hoek JA, Lins RL, ten Cate JW (1991) Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. *ASAIO Trans* 37(3):M459–461
  55. Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA (2002) Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. *Am J Kidney Dis* 40(3):531–538
  56. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. *Thromb Haemost* 62(3):940–944
  57. Leizorovicz A, Bara L, Samama MM, Haugh MC (1993) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. *Haemostasis* 23(Suppl 1):89–98
  58. Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME (2004) Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. *J Thromb Haemost* 2(8):1299–1304
  59. Brophy DF, Martin EJ, Gehr TW, Carr ME Jr (2004) Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. *Am J Kidney Dis* 44(2):270–277
  60. Al Dieri R, Alban S, Beguin S, Hemker HC (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. *J Thromb Haemost* 4(1):83–89
  61. Lim W (2010) Using low molecular weight heparin in special patient populations. *J Thromb Thrombolysis* 29(2):233–240
  62. Boneu B, de Moerloose P (2001) How and when to monitor a patient treated with low molecular weight heparin. *Semin Thromb Hemost* 27(5):519–522
  63. Smith BS, Gandhi PJ (2001) Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. *J Thromb Thrombolysis* 11(1): 39–48